- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04260594
Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus
Randomized, Open, Multicenter Study on the Efficacy and Safety of Arbidol Hydrochloride Tablets in Treating Pneumonia in Patients Infected With Novel Coronavirus (2019-ncov).
Study Overview
Detailed Description
In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of pneumonia of unknown cause. In a short time, Chinese scientists had shared the genome information of a novel coronavirus (2019-nCoV) from these pneumonia patients and developed a real-time reverse transcription PCR (real time RT-PCR) diagnostic assay. The number of cases of infection with 2019-nCoV identified in Wuhan increased markedly over the later part of January 2020, with cases identified in multiple other Provinces of China and internationally. Mathematical models of the expansion phase of the epidemic suggested that sustained person-to-person transmission is occurring, and the R-zero is substantially above 1, the level required for a self-sustaining epidemic in human populations.
There is currently no specific treatment for 2019-ncov-infected pneumonia. Arbidol tablet is a non-nucleoside broad-spectrum antiviral drug with immune-enhancing effect. Abidor is pharmacodynamic in vitro against a variety of coronaviruses.This is a randomized, open, multicenter clinical study of pneumonic subjects diagnosed with 2019-ncov infection. The main objective was to compare the viral negative conversion rate in the first week after the subjects were randomized to arbidol plus basic treatment.
In this study, 380 eligible patients with pneumonia diagnosed with 2019-ncov infection were randomly assigned to one of two treatment groups at a 1:1 ratio.
patients will receive one of two treatment regimens: A .Abidor tablets + basic treatment B. basic treatment Arbidol tablets: take 2 tablets/time, 3 times/day for 14-20 days Basic treatment :The basic treatment used by the investigator was based on the condition of the patient.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200025
- Ruijin Hospital, Medical School of Shanghai Jiaotong University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- aged 18 to 65 years old (including 18 and 65 years);
- male and non-pregnant female;
- respiratory tract specimens or hematology samples detected positive results of SARS-CoV-2 by real-time transcriptase polymerase chain reaction (RT-PCR).
- mild clinical status, defined as having mild clinical symptoms but no signs of pneumonia on imaging or moderate clinical status, defined as having fever, respiratory symptoms and pneumonia on imaging or severe clinical status, defined as having an oxygen saturation (SaO2) of 93% or less at ambient air or a ratio of the partial pressure of oxygen (PaO2) to the fraction of inspired oxygen (FiO2) at or below 400 mgHg, which can be rectified by oxygen inhalation through nasal catheter or face mask.
Exclusion Criteria:
included a physician decision that involvement in the trial was not in the patient's best interest, known allergic reaction and / or severe allergic to arbidol, blood system dysfunction (platelet count <100×109/L, hemoglobin level <90g/L), severe liver dysfunction (total bilirubin level >2 times the normal upper limit, aspartic aminotransferase and alanine aminotransferase levels >3 times normal upper limit),severe renal dysfunction (serum creatinine >1.5 times the upper limit of normal value, calculated creatinine clearance rate <50 ml/min), treated with arbidol before admission, history of severe heart disease or clinically significant arrhythmia considered unsafe for the trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arbidol tablets + basic treatment
|
Arbidol tablets: take 2 tablets/time, 3 times/day for 14-20 days
Other Names:
basic treatment
|
Sham Comparator: basic treatment
|
basic treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Virus negative conversion rate in the first week
Time Frame: first week
|
first week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Virus negative conversion rate
Time Frame: 14-20 days
|
virus negative conversion rate in second week, overall virus negative conversion rate
|
14-20 days
|
Antipyretic rate
Time Frame: 14-20 days
|
defined as: the rate of Axillary temperature ≤37.5 ℃ for at least 48h
|
14-20 days
|
Symptom relief time
Time Frame: 14-20 days
|
time to relieve symptoms of fever, cough, dyspnea, myalgia, etc
|
14-20 days
|
Finger oxygen improvement rate
Time Frame: 14-20 days
|
no adjuvant oxygen therapy, resting oxygen saturation>95%, oxygenation index>350
|
14-20 days
|
Disease progression rate
Time Frame: 14-20 days
|
Mild, common type progression to severe or critical illness rate
|
14-20 days
|
Mortality rate
Time Frame: 14-20 days
|
14-20 days
|
|
Incidence of severe adverse reactions
Time Frame: 14-20 days
|
14-20 days
|
|
Change curve of peripheral blood lymphocyte count
Time Frame: 14-20 days
|
14-20 days
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Abdrcspc202001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on 2019-nCoV
-
Beijing Children's HospitalThe First Affiliated Hospital of Anhui Medical University; Shengjing Hospital; China-Japan Friendship Hospital and other collaboratorsUnknown
-
Tongji HospitalUnknown
-
Chongqing Medical UniversityWithdrawn
-
Peking Union Medical College HospitalTongji HospitalUnknown
-
Sinovac Life Sciences Co., Ltd.RecruitingInfection of Upper Respiratory Tract Caused by 2019-nCoVChina
-
Leidos Life SciencesUnited States Department of DefenseActive, not recruitingCOVID-19 | Covid19 | Coronavirus Disease 2019 | SARS-CoV-2 Infection | SARS-CoV-2 Acute Respiratory Disease | COVID-19 Pandemic | COVID-19 Virus Infection | COVID-19 Virus Disease | 2019 Novel Coronavirus Disease | 2019 Novel Coronavirus Infection | 2019-nCoV Disease | 2019-nCoV InfectionUnited States
-
Leidos Life SciencesUnited States Department of DefenseWithdrawnCOVID-19 | Covid19 | Coronavirus Disease 2019 | SARS-CoV-2 Infection | SARS-CoV-2 Acute Respiratory Disease | COVID-19 Pandemic | COVID-19 Virus Infection | COVID-19 Virus Disease | 2019 Novel Coronavirus Disease | 2019 Novel Coronavirus Infection | 2019-nCoV Disease | 2019-nCoV Infection
-
Leidos Life SciencesUnited States Department of DefenseTerminatedCOVID-19 | Covid19 | Coronavirus Disease 2019 | SARS-CoV2 Infection | SARS-CoV-2 Acute Respiratory Disease | COVID-19 Pandemic | COVID-19 Virus Infection | COVID-19 Virus Disease | 2019 Novel Coronavirus Disease | 2019 Novel Coronavirus Infection | 2019-nCoV Disease | 2019-nCoV InfectionUnited States
-
Tongji HospitalUnknown
Clinical Trials on Arbidol
-
Shengjing HospitalEnrolling by invitation
-
PharmstandardUnknownInfluenzaRussian Federation
-
Capital Medical UniversityPeking University; University of Oxford; National Institute for Viral Disease...Unknown
-
Yale UniversityCompletedPleural Effusion | Thoracic EffusionUnited States
-
Atabay Kimya Sanayi Ticaret A.S.Novagenix Bioanalytical Drug R&D Center; Farmagen Ar-Ge Biyot. Ltd. StiUnknown
-
Second Affiliated Hospital of Wenzhou Medical UniversityWanbangde Pharmaceutical Group Co., LTDUnknown
-
Guangzhou 8th People's HospitalCompletedCoronavirus InfectionsChina
-
Beijing YouAn HospitalCancer Institute and Hospital, Chinese Academy of Medical Sciences; Renmin... and other collaboratorsUnknownNovel Coronavirus Infectious Disease (COVID-19)